Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $6.1667.

Several brokerages have commented on CNTX. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Piper Sandler boosted their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Guggenheim restated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Maxim Group cut their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Finally, Wall Street Zen upgraded Context Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNTX. Seven Fleet Capital Management LP bought a new position in shares of Context Therapeutics during the 1st quarter valued at approximately $500,000. Bank of America Corp DE lifted its position in Context Therapeutics by 12,213.8% in the first quarter. Bank of America Corp DE now owns 114,888 shares of the company’s stock worth $301,000 after buying an additional 113,955 shares during the last quarter. Octagon Capital Advisors LP purchased a new position in Context Therapeutics during the first quarter worth $13,755,000. OMERS ADMINISTRATION Corp purchased a new position in Context Therapeutics during the first quarter worth $211,000. Finally, Sanctuary Advisors LLC bought a new position in Context Therapeutics during the first quarter valued at $51,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.65 on Monday. The company has a market capitalization of $59.99 million, a price-to-earnings ratio of -1.55 and a beta of 1.75. Context Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.62. The stock’s 50 day moving average is $1.60 and its 200-day moving average is $2.03.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. As a group, equities research analysts predict that Context Therapeutics will post -0.39 earnings per share for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.